Novartis Ag (NVSEF) Cash from Investing Activities Growth (5y) (2014 - 2025)

Novartis Ag (NVSEF) Cash from Investing Activities Growth (5y) (2014 - 2025) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Novartis Ag - - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -29.80%
Jun 30, 2025 -39.47%
Dec 31, 2024 -66.90%
Jun 30, 2024 -77.09%
Dec 31, 2023 80.90%
Jun 30, 2023 -17.24%
Dec 31, 2022 -18.15%
Jun 30, 2022 -108.23%
Dec 31, 2021 24.92%
Sep 30, 2021 -12.43%
Jun 30, 2021 16.71%
Mar 31, 2021 27.67%
Dec 31, 2019 1,266.51%
Jun 30, 2019 1,117.67%
Dec 31, 2018 -44.46%
Sep 30, 2018 -1,483.09%
Jun 30, 2018 2,267.32%
Dec 31, 2017 -15.86%
Jun 30, 2017 -1,226.55%
Dec 31, 2016 -1,493.64%